Resultats de la cerca - Annette Reichardt
- Mostrar 1 - 6 resultats de 6
-
1
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors per Sebastian Bauer, R A Hilger, Thomas Mühlenberg, Florian Grabellus, James Nagarajah, Mathias Hoiczyk, Annette Reichardt, Marit Ahrens, Peter Reichardt, Susanne Grünewald, M. E. Scheulen, A. Pustowka, E Bock, Martin Schüler, Daniel Pink
Publicat 2014Artigo -
2
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial per Heikki Joensuu, Annette Reichardt, Mikael Eriksson, Peter Hohenberger, Kjetil Boye, Silke Cameron, Lars H. Lindner, Philipp J. Jost, Sebastian Bauer, J. Schütte, S. Lindskog, Raija Kallio, Panu Jaakkola, Dorota Goplen, Eva Wardelmann, Peter Reichardt
Publicat 2024Artigo -
3
<i>KIT</i> and <i>PDGFRA</i> Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial per Heikki Joensuu, Eva Wardelmann, Mikael Eriksson, Annette Reichardt, Kirsten Sundby Hall, Jochen Schütte, Silke Cameron, Peter Hohenberger, Harri Sihto, Philipp J. Jost, Lars H. Lindner, Sebastian Bauer, Bengt Nilsson, Raija Kallio, Tommi Pesonen, Peter Reichardt
Publicat 2023Artigo -
4
Effect of <i>KIT</i> and <i>PDGFRA</i> Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib per Heikki Joensuu, Eva Wardelmann, Harri Sihto, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Jörg T. Hartmann, Daniel Pink, Silke Cameron, Peter Hohenberger, Salah‐Eddin Al‐Batran, M. Schlemmer, Sebastian Bauer, Bengt Nilsson, Raija Kallio, Jouni Junnila, Aki Vehtari, Peter Reichardt
Publicat 2017Artigo -
5
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors per Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Bárbara Hermes, J. Schütte, Silke Cameron, Peter Hohenberger, Philipp J. Jost, Salah‐Eddin Al‐Batran, Lars H. Lindner, Sebastian Bauer, Eva Wardelmann, Bengt Nilsson, Raija Kallio, Panu Jaakkola, Jouni Junnila, Thor Alvegård, Peter Reichardt
Publicat 2020Artigo -
6
A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors per George D. Demetri, Paolo G. Casali, Jean‐Yves Blay, Margaret von Mehren, Jeffrey A. Morgan, Rossella Bertulli, Isabelle Ray‐Coquard, Philippe A. Cassier, Monica Davey, Hossein Borghaei, Daniel Pink, Maria Dębiec‐Rychter, Wing K. Cheung, Stuart M. Bailey, Maria Luisa Veronese, Annette Reichardt, Elena Fumagalli, Peter Reichardt
Publicat 2009Artigo
Eines de cerca:
Matèries relacionades
GiST
Imatinib
Internal medicine
Medicine
Myeloid leukemia
Stromal cell
Imatinib mesylate
Oncology
Gastroenterology
Adjuvant
Surgery
Adverse effect
Cancer
Clinical trial
PDGFRA
Pharmacology
Tyrosine-kinase inhibitor
Astrobiology
Biochemistry
Biology
Cancer research
Clinical endpoint
Cohort
Cohort study
Environmental health
Gene
Histone
Histone deacetylase
Nausea
Nilotinib